Dose-independent pharmacokinetics of clindamycin after intravenous and oral administration to rats: Contribution of gastric first-pass effect to low bioavailability

International Journal of Pharmaceutics

Volumn 332, Issue 1-2, 2007, Pages 17-23

  Yang, Si H ^a   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

Author keywords

Clindamycin; Dose independent pharmacokinetics; Gastric first pass effect; Intravenous, oral, intraportal, intragastric, and intraduodenal administration; Rats

Indexed keywords

CLINDAMYCIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG STABILITY; FIRST PASS EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MEAN RESIDENCE TIME; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL ANALYSIS; STOMACH PH;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; CLINDAMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG STABILITY; DUODENUM; HYDROGEN-ION CONCENTRATION; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; STOMACH;

EID: 33846867258     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.11.019     Document Type: Article

References (22)

1. Chiou W.L. Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J. Pharmacokinet. Biopharm. 6 (1978) 539-546
2. Chiou W.L. New calculation method for mean apparent drug volume of distribution and application to rational dosage regimen. J. Pharm. Sci. 68 (1979) 1068-1069
3. Chiou W.L. Potential pitfalls in the conventional pharmacokinetic studies: effects of the initial mixing of drug in blood and the pulmonary first-pass elimination. J. Pharmacokinet. Biopharm. 7 (1979) 527-536
4. Chiou W.L. New calculation method of mean total body clearance of drugs and its application to dosage regimens. J. Pharm. Sci. 69 (1980) 90-91
5. Cho S.H., Im H.T., Park W.S., Ha Y.H., Choi Y.W., and Lee K.T. Simple method for the assay of clindamycin in human plasma by reversed-phase high-performance liquid chromatography with UV detector. Biomed. Chromatogr. 19 (2005) 783-787
6. Davies B., and Morris T. Physiological parameters in laboratory animals and humans. Pharm. Res. 10 (1993) 1009-1095
7. DeHaan R.M., Metzler C.M., Schellenberg D., VandenBosch W.D., and Masson E.L. Pharmacokinetic studies of clindamycin hydrochloride in humans. Int. J. Clin. Pharmacol. 6 (1972) 105-119
8. Eatman F.B., Colburn W.A., Boxenbaum H.G., Weinfeld R.E., Ronfeld R., Weissman L., Gibaldi M., and Kaplan S.A. Pharmacokinetics of diazepam following multiple dose oral administration to healthy human subjects. J. Pharmacokinet. Biopharm. 5 (1977) 481-494
9. Gatti G., Flaherty J., Bubp J., White J., Borin M., and Gambertoglio J. Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS. Antimicrob. Agents Chemother. 37 (1993) 1137-1143
10. Gatti G., Malena M., Casazza R., Borin M., Bassetti M., and Cruciani M. Penetration of clindamycin and its metabolite N-demethylclindamycin into cerebrospinal fluid following intravenous infusion of clindamycin phosphate in patients with AIDS. Antimicrob. Agents Chemother. 42 (1998) 3014-3017
11. Gibaldi M., and Perrier D. Pharmacokinetics. second ed. (1982), Marcel-Dekker, New York
12. Kim S.H., Choi Y.M., and Lee M.G. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J. Pharmacokinet. Biopharm. 21 (1993) 1-17
13. Lee M.G., and Chiou W.L. Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J. Pharmacokinet. Biopharm. 11 (1983) 623-640
14. Lee H.-J., and Chiou W.L. Erythrocytes as barriers for drug elimination in the isolated rat liver. I. Doxorubicin. Pharm. Res. 6 (1989) 833-839
15. Lee H.-J., and Chiou W.L. Erythrocytes as barriers for drug elimination in the isolated rat liver. II. Propranolol. Pharm. Res. 6 (1989) 840-843
16. Lee M.G., Chen M.-L., Huang S.-M., and Chiou W.L. Pharmacokinetics of drugs in blood I. Unusual distribution of gentamicin. Biopharm. Drug Dispos. 2 (1981) 89-97
17. Mitruka B.M., and Rawnsley H.M. Clinical Biomedical and Hematological Reference Values in Normal Experimental Animals and Normal Humans. second ed. (1981), Masson Publishing USA Inc., New York
18. Murakami T., Nakanishi M., Yoshimori T., Okamura N., Norikura R., and Mizojiri K. Separate assessment of intestinal and hepatic first-pass effects using a rat model with double cannulation of the portal and jugular veins. Drug Metab. Pharmacokinet. 18 (2003) 242-260
19. Shim H.J., Lee E.J., Kim S.H., Kim S.H., You M., Kwon J.W., Kim W.B., and Lee M.G. Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique. Biopharm. Drug Dispos. 21 (2000) 285-291
20. Sun F.F. Metabolism of clindamycin. II: Urinary excretion products of clindamycin in rat and dog. J. Pharm. Sci. 62 (1973) 1657-1662
21. Wynalda M.A., Hutzler J.M., Koets M.D., Podoll T., and Wienkers L.C. In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug Metab. Dispos. 31 (2003) 878-887
22. Yu S.Y., Bae S.K., Kim E.J., Kim Y.G., Kim S.O., Lee D.H., Lim H., and Lee M.G. Dose-independent pharmacokinetics of a new reversible proton pump inhibitor, KR-60436, after intravenous and oral administration to rats: gastrointestinal first-pass effect. J. Pharm. Sci. 92 (2003) 1592-1603